Wells Fargo Downgrades Regeneron Pharmaceuticals (BMV:REGN)

Wells Fargo downgraded Regeneron Pharmaceuticals (REGN) from Overweight to Equal-Weight on May 30, 2025. Recent filings indicate that Jpmorgan Chase decreased its REGN holdings by 24.76% to 5,658K shares, while Capital International Investors reduced their position by 18.75% to 3,989K shares; both firms also significantly decreased their portfolio allocation in REGN. Conversely, Vanguard Total Stock Market Index Fund Investor Shares, Vanguard 500 Index Fund Investor Shares, and Geode Capital Management increased their holdings slightly, though all three decreased their portfolio allocation in REGN.

Analysis

Regeneron Pharmaceuticals (REGN) experienced a notable shift in sentiment following Wells Fargo's downgrade from Overweight to Equal-Weight on May 30, 2025. This analyst action is accompanied by significant divestment from major institutional investors. Jpmorgan Chase reduced its holdings by 24.76% to 5.658 million shares, drastically cutting its portfolio allocation in REGN by 92.61%. Capital International Investors also decreased its position by 18.75% to 3.989 million shares, with a corresponding portfolio allocation reduction of 21.50%. While passive investment vehicles such as Vanguard Total Stock Market Index Fund Investor Shares and Vanguard 500 Index Fund Investor Shares reported minor increases in share ownership of 0.26% and 2.51% respectively, and Geode Capital Management increased its holdings by 1.70%, these firms also reduced their portfolio allocation in REGN by 6.87%, 6.75%, and a substantial 51.47% respectively. This broad trend of decreased portfolio allocation, even among firms with slight share increases, coupled with a specific REGN sentiment score of -0.7 (moderately negative), signals growing caution among institutional investors regarding the stock's outlook.

Key Decisions for Investors

• Investors should consider the Wells Fargo downgrade and the significant selling pressure from active institutional managers as key indicators of potential headwinds for Regeneron Pharmaceuticals.
• The marked decrease in portfolio allocation to REGN across multiple large funds, including those with marginal share increases, warrants a cautious stance and a review of exposure to the stock.
• Monitor for further analyst commentary, subsequent institutional trading patterns, and company-specific news that could either confirm or counter this bearish sentiment before making significant investment adjustments.